Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires

Rhea-AI Filing Summary

Propanc Biopharma reported a board change. Effective February 20, 2026, long-serving director Dr. Julian Kenyon retired from the Board of Directors to focus on his personal and family life, but he will continue to support the company as a medical advisor.

The Board filled the resulting vacancy the same day by appointing Dr. Ralf Brandt as a new director. Dr. Brandt is an experienced pharmaceutical and oncology research executive with more than thirty years in drug discovery, angiogenesis, and pre-clinical development, and has advanced over 50 compounds to clinical studies.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001517681 0001517681 2026-02-20 2026-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 20, 2026

PROPANC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42806		33-0662986
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

302, 6 Butler Street

Camberwell, VIC, 3124 Australia

(Address of registrant’s principal executive office) (Zip code)

+61-03-9882-0780

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		PPCB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective February 20, 2026, Dr. Julian Kenyon retired and stepped down from the Board of Directors (the “Board”) of Propanc Biopharma, Inc. (the “Company”) to focus on his personal and family life. Dr. Kenyon will remain a medical advisor to the Company. That same day, the Board filled the vacancy left by Dr. Kenyon and appointed Dr. Ralf Brant to serve on the Board until his removal or resignation.

Dr. Brandt is a pharmaceutical and oncology research executive with over thirty years of experience in drug discovery, oncology, angiogenesis, and pre-clinical development. He has held senior leadership roles including CEO and Founder of vivoPharm Pty Ltd and vivoPharm Global Pty Ltd, President Discovery at CGIX and VYANT Bio Inc., and executive positions at Novartis and Bionomics Ltd. Dr. Brandt has advanced more than 50 compounds to clinical studies by generating and presenting non-clinical data to client and/or regulatory bodies, holds five international patents, and authored 27 peer-reviewed publications and several book chapters. He is an expert in in-vivo and in-vitro pharmacology, cell biology, animal model development, GLP compliance, and translational research, and serves on several scientific advisory boards globally including Propanc Biopharma Inc. He earned his PhD in Biochemistry from the Max-Delbrück Center for Molecular Medicine, Berlin, and has received multiple awards including the prestigious Fogarty Fellowship (NIH, USA).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
10.1		Director Agreement dated February 20, 2026 by and between Propanc Biopharma, Inc. and Dr. Ralf Brandt
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2026	PROPANC BIOPHARMA, INC.
	By:	/s/ James Nathanielsz
	Name:	James Nathanielsz
	Title:	Chief Executive Officer and Chief Financial Officer

FAQ

What board change did Propanc Biopharma (PPCB) announce on February 20, 2026?

Propanc Biopharma announced that director Dr. Julian Kenyon retired from its Board on February 20, 2026. He stepped down to focus on personal and family life but will continue contributing as a medical advisor to the company going forward.

Who joined the Propanc Biopharma (PPCB) Board of Directors to replace Dr. Kenyon?

Dr. Ralf Brandt was appointed to the Board on February 20, 2026, to fill the vacancy. He brings extensive experience in oncology, drug discovery, and pre-clinical development, including leadership roles at vivoPharm, CGIX, VYANT Bio, Novartis, and Bionomics.

What is Dr. Ralf Brandt’s background relevant to Propanc Biopharma (PPCB)?

Dr. Brandt is a seasoned pharmaceutical and oncology research executive with over thirty years of experience. He has advanced more than 50 compounds to clinical studies, holds multiple international patents, and has authored peer-reviewed publications and book chapters.

Will Dr. Julian Kenyon remain involved with Propanc Biopharma (PPCB) after retiring from the Board?

Yes. Although Dr. Julian Kenyon retired from Propanc Biopharma’s Board of Directors, he will remain involved as a medical advisor. This allows the company to retain his clinical and scientific insight while transitioning board responsibilities to Dr. Ralf Brandt.

What exhibit was included with Propanc Biopharma’s (PPCB) 8-K about the board changes?

The filing included Exhibit 10.1, a Director Agreement dated February 20, 2026 between Propanc Biopharma and Dr. Ralf Brandt. It also referenced Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

How long has Dr. Ralf Brandt been active in oncology and drug development before joining PPCB’s board?

Dr. Brandt has more than thirty years of experience in drug discovery, oncology, angiogenesis, and pre-clinical development. His career includes senior leadership roles and responsibility for progressing numerous compounds from non-clinical work into clinical studies.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 107.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB